On a webcast, Compass Pathways management shared further insight into this morning’s Phase 3 program readout, which featured a first look at topline data from COMP006 and 26-week data from COMP005. We covered that topline in depth, via in-house analysis and discussion with CEO Kabir Nath and CMO Guy Goodwin: Breaking: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Invites…
